MedTrace Logo

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

NCT06665412 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2024-10-30

No results posted yet for this study

Summary

The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects.

The main efficacy is checked by MMR rate by 12 months from IP treatment.

Conditions

  • Chronic Phase Ph+ Chronic Myeloid Leukemia

Interventions

DRUG

Radotinib Hydrochloride

200mg BID, every day up to 12months

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Na Yun Kim · Il-Yang Pharm. Co., Ltd.

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06665412 on ClinicalTrials.gov